ARGX241220C410000
- 93.51
- 0.000.00%
argenx SE Newsroom
Argenx to Present at Upcoming Investor Conferences
Argenx Is Maintained at Outperform by Evercore ISI Group
Evercore Maintains Argenx SE(ARGX.US) With Buy Rating, Maintains Target Price $706
Oppenheimer Maintains Argenx SE(ARGX.US) With Buy Rating, Raises Target Price to $675
Jefferies Maintains Argenx SE(ARGX.US) With Buy Rating, Maintains Target Price $689
Jefferies Sticks to Their Buy Rating for Argenx Se (ARGX)
A Quick Look at Today's Ratings for Argenx SE(ARGX.US), With a Forecast Between $606 to $770
Express News | Argenx SE : Raymond James Raises Target Price to $770 From $688
Argenx Se's Promising Clinical Advancements and Positive ALKIVIA Study Results Underpin Buy Rating
European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading
Sector Update: Health Care Stocks Edge Higher Premarket Wednesday
Sector Update: Health Care
Argenx to Continue Development of Autoimmune Disease Drug After Phase 2/3 Data
Argenx SE Boosts Myositis Treatment Development
Argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies
Steritas Announces Collaboration With Argenx to Advance Evidence for Novel Steroid-sparing Therapeutics
Morgan Stanley Maintains Argenx SE(ARGX.US) With Buy Rating, Raises Target Price to $675
Truist Financial Maintains Argenx SE(ARGX.US) With Buy Rating
Global Companies With at Least 50% U.S. Revenue Exposure as Trump Eyes Tariffs: BofA
Is Argenx SE (ARGX) the Best Immunotherapy Stock to Buy Now?